Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Robust scoring of selective drug responses for patient-tailored therapy selection.
Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T. Chen Y, et al. Among authors: miettinen jj. Nat Protoc. 2024 Jan;19(1):60-82. doi: 10.1038/s41596-023-00903-x. Epub 2023 Nov 23. Nat Protoc. 2024. PMID: 37996540 Review.
Nordcan.R: a new tool for federated analysis and quality assurance of cancer registry data.
Larønningen S, Skog A, Engholm G, Ferlay J, Johannesen TB, Kristiansen MF, Knoors D, Kønig SM, Olafsdottir EJ, Pejicic S, Pettersson D, Skovlund CW, Storm HH, Tian H, Aagnes B, Miettinen J. Larønningen S, et al. Among authors: miettinen j. Front Oncol. 2023 Aug 8;13:1098342. doi: 10.3389/fonc.2023.1098342. eCollection 2023. Front Oncol. 2023. PMID: 37614501 Free PMC article.
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.
Casado P, Rio-Machin A, Miettinen JJ, Bewicke-Copley F, Rouault-Pierre K, Krizsan S, Parsons A, Rajeeve V, Miraki-Moud F, Taussig DC, Bödör C, Gribben J, Heckman C, Fitzgibbon J, Cutillas PR. Casado P, et al. Among authors: miettinen jj. Signal Transduct Target Ther. 2023 Feb 27;8(1):80. doi: 10.1038/s41392-022-01288-1. Signal Transduct Target Ther. 2023. PMID: 36843114 Free PMC article.
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vänttinen I, Nygren P, Klievink J, Bouhlal J, Pölönen P, Zhang Q, Adnan-Awad S, Mancebo-Pérez C, Saad J, Miettinen J, Javarappa KK, Aakko S, Ruokoranta T, Eldfors S, Heinäniemi M, Theilgaard-Mönch K, Wartiovaara-Kautto U, Keränen M, Porkka K, Konopleva M, Wennerberg K, Kontro M, Heckman CA, Mustjoki S. Kuusanmäki H, et al. Among authors: miettinen j. Blood. 2023 Mar 30;141(13):1610-1625. doi: 10.1182/blood.2021011094. Blood. 2023. PMID: 36508699 Free PMC article.
CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia.
Grey W, Rio-Machin A, Casado P, Grönroos E, Ali S, Miettinen JJ, Bewicke-Copley F, Parsons A, Heckman CA, Swanton C, Cutillas PR, Gribben J, Fitzgibbon J, Bonnet D. Grey W, et al. Among authors: miettinen jj. Sci Transl Med. 2022 Jun 22;14(650):eabn3248. doi: 10.1126/scitranslmed.abn3248. Epub 2022 Jun 22. Sci Transl Med. 2022. PMID: 35731890 Free PMC article.
Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.
Gebraad A, Ohlsbom R, Miettinen JJ, Emeh P, Pakarinen TK, Manninen M, Eskelinen A, Kuismanen K, Slipicevic A, Lehmann F, Nupponen NN, Heckman CA, Miettinen S. Gebraad A, et al. Among authors: miettinen jj. Cells. 2022 May 7;11(9):1574. doi: 10.3390/cells11091574. Cells. 2022. PMID: 35563880 Free PMC article.
101 results